Ovarian Cancer
📧 Sign up to get email alerts when something new happens for Ovarian Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-03-31Clinical Trial Update: Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors [Phase 2]
Phase 2 trial exploring DPX-Survivac with low-dose cyclophosphamide and pembrolizumab in selected advanced solid tumors; currently active/no…
-
CLINICAL_TRIALS trial_result · 2022-03-15Clinical Trial Update: Tranexamic Acid in Surgery of Advanced Ovarian Cancer [Phase 4]
Phase 4 clinical trial update for tranexamic acid in surgery for advanced ovarian cancer; trial completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-03-09Clinical Trial Update: Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers [Phase 1]
Phase 1 trial assessing cabiralizumab with nivolumab in selected advanced cancers has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2022-03-08Clinical Trial Update: Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer [Phase 2]
Phase 2 clinical trial evaluating bupropion hydrochloride to improve sexual desire in women with breast or gynecologic cancers has completed…
-
CLINICAL_TRIALS trial_result · 2022-02-24Clinical Trial Update: Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer [Phase 3]
Phase 3 trial evaluating symptom benefit rate of trabectedin plus pegylated liposomal doxorubicin (PLD) in recurrent ovarian cancer was term…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-02-18Clinical Trial Update: Efficacy of Neoadjuvant Hyperthermic Intraperitoneal Chemotherapy in Advanced High-grade Serous Ovarian Cancer (the NHIPEC Trial) [Phase 2]
Phase 2 trial investigating neoadjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced high-grade serous ovarian cancer; sta…
-
CLINICAL_TRIALS trial_result · 2022-02-11Clinical Trial Update: ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients [Phase 3]
Phase 3 ARIEL4 trial comparing rucaparib to chemotherapy in BRCA-mutant ovarian, fallopian tube, or primary peritoneal cancer has completed …
-
CLINICAL_TRIALS trial_result · 2022-02-09Clinical Trial Update: INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer [Phase 3]
Phase 3 randomized trial in ovarian cancer completed; no additional details provided in the snippet.
-
CLINICAL_TRIALS trial_result · 2022-02-07Clinical Trial Update: Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer [Phase 1, Phase 2]
A clinical trial evaluating topotecan in combination with gefitinib (Iressa) for ovarian, peritoneal, or fallopian tube cancers has complete…
-
CLINICAL_TRIALS trial_result · 2022-02-04Clinical Trial Update: OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer [Phase 3]
Phase 3 clinical trial results update for OTL38 used in intra-operative imaging of folate receptor positive ovarian cancer has completed wit…
-
CLINICAL_TRIALS trial_result · 2022-01-26Clinical Trial Update: PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer [Phase 4]
Phase 4 clinical trial update of PARP inhibitor as oral maintenance in low-risk ovarian cancer is underway, status currently UNKNOWN.
-
CLINICAL_TRIALS trial_result · 2022-01-19Clinical Trial Update: A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy [Phase 2]
Phase 2 study results assess niraparib in combination with bevacizumab as maintenance therapy for advanced ovarian cancer after response to …
-
CLINICAL_TRIALS trial_result · 2022-01-14Clinical Trial Update: IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery [Phase 2]
Phase 2 trial update on IGFBP-2 vaccine with combination chemotherapy for stage III-IV ovarian, fallopian tube, or primary peritoneal cancer…
-
CLINICAL_TRIALS trial_result · 2021-12-28Clinical Trial Update: A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer [Phase 2]
Phase 2 trial evaluating bevacizumab with fluzoparib and chemotherapy or fluzoparib in ovarian cancer.
-
CLINICAL_TRIALS withdrawal · 2021-12-23Clinical Trial Update: DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma [Phase 3]
Phase 3 trial of DCVAC/OvCa with standard of care for relapsed ovarian/fallopian tube/peritoneal cancer has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2021-12-21Clinical Trial Update: Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer [Phase 1]
Phase 1 trial evaluating a radiolabeled monoclonal antibody in patients with advanced ovarian epithelial cancer has completed, with results …
-
CLINICAL_TRIALS trial_result · 2021-12-20Clinical Trial Update: Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients [Phase 2]
Phase 2 study evaluating pembrolizumab in recurrent, platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers with CPS > 1…
-
CLINICAL_TRIALS trial_result · 2021-12-13Clinical Trial Update: A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors [Phase 1]
A Phase 1 dose-escalation study of PF-06801591 in multiple solid tumors including melanoma, head and neck cancer, ovarian cancer, sarcoma, n…
-
CLINICAL_TRIALS trial_result · 2021-12-08Clinical Trial Update: A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer [Phase 3]
Phase 3 trial comparing TQB2450 with Anlotinib capsules versus Paclitaxel weekly for relapsed platinum-resistant ovarian cancer.
-
CLINICAL_TRIALS trial_result · 2021-11-30Clinical Trial Update: TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer [Phase 2]
Phase 2 trial of TPIV200/huFR-1 vaccine plus durvalumab in platinum-resistant ovarian cancer completed; results posted in 2021.
-
FDA approval · 2021-11-29FDA Approved: CYTALUX — Original Application (On Target Laboratories, Inc.)
The FDA approved Cytalux (pafolacianine injection) from On Target Laboratories for intraoperative visualization of folate receptor–positive …
-
CLINICAL_TRIALS trial_result · 2021-11-15Clinical Trial Update: A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer [Phase 1, Phase 2]
Clinical trial update for an autologous oxidized tumor cell lysate vaccine in recurrent ovarian/fallopian tube/primary peritoneal cancer; tr…
-
CLINICAL_TRIALS trial_result · 2021-10-29Clinical Trial Update: Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients
Non-interventional European study evaluating trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer has completed with …
-
CLINICAL_TRIALS trial_result · 2021-10-11Clinical Trial Update: Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients [Phase 3]
Phase 3 multicenter trial evaluating maintenance monotherapy with olaparib in platinum-sensitive relapsed non-germline BRCA mutated ovarian …
-
CLINICAL_TRIALS trial_result · 2021-09-30Clinical Trial Update: Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED) [Phase 3]
Phase 3 study evaluating EC145 in combination with Doxil for platinum-resistant ovarian cancer was terminated.